Display options
Cite
Rutherford G, Lithgow B, Moussavi Z. Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study. J Exp Neurosci. 2015;9:43-51doi: 10.4137/JEN.S24004.
Rutherford, G., Lithgow, B., & Moussavi, Z. (2015). Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study. Journal of experimental neuroscience, 943-51. https://doi.org/10.4137/JEN.S24004
Rutherford, Grant, et al. "Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study." Journal of experimental neuroscience vol. 9 (2015): 43-51. doi: https://doi.org/10.4137/JEN.S24004
Rutherford G, Lithgow B, Moussavi Z. Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study. J Exp Neurosci. 2015 Jun 03;9:43-51. doi: 10.4137/JEN.S24004. eCollection 2015. PMID: 26064066; PMCID: PMC4457230.
Copy Download .nbib Format: NLM
Share it on

J Exp Neurosci. 2015 Jun 03;9:43-51. doi: 10.4137/JEN.S24004. eCollection 2015.

Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study.

Journal of experimental neuroscience

Grant Rutherford, Brian Lithgow, Zahra Moussavi

Affiliations

  1. Biomedical Engineering Program, University of Manitoba, Winnipeg, Canada.
  2. Biomedical Engineering Program, University of Manitoba, Winnipeg, Canada. ; Monash-Alfred Psychiatry Research Center, Melbourne, Australia.
  3. Biomedical Engineering Program and Psychiatry Department, University of Manitoba, Winnipeg, Canada.

PMID: 26064066 PMCID: PMC4457230 DOI: 10.4137/JEN.S24004

Abstract

Repetitive transcranial magnetic stimulation (rTMS) uses a magnetic coil to induce an electric field in brain tissue. As a pilot study, we investigated the effect of rTMS treatment on 10 volunteers with Alzheimer's disease (AD) in a two-stage study. The first stage consisted of a double-blind crossover study with real and sham treatments. Each treatment block consisted of 13 sessions over 4 weeks. During each session, 2000 TMS pulses at 90%-100% of resting motor threshold were applied to dorsolateral prefrontal cortex bilaterally, and the patients were kept cognitively active by object/action naming during the treatment. The second stage was an open-label study, in which the same treatments were performed in 2-week blocks (10 sessions) approximately every 3 months as follow-up treatments on six of the volunteers, who completed the first stage of the study. Primary outcome measures were the Montreal Cognitive Assessment (MOCA) and the Alzheimer's Disease Assessment Scale-cognitive subscale. The secondary outcome measures were the Revised Memory and Behavior Checklist as well as our team's custom-designed cognitive assessments. The results showed a noticeably stronger improvement on all assessments during the real treatment as compared to the sham treatment. The changes in MOCA scores as well as our designed cognitive assessment were found to be statistically significant, with particularly strong results in the six volunteers who were in the early stages of the disease. The long-term trends observed in the second stage of the study also showed generally less decline than would be expected for their condition. It appears that rTMS can be an effective tool for improving the cognitive abilities of patients with early to moderate stages of AD. However, the positive effects of rTMS may persist for only up to a few weeks. Specific skills being practiced during rTMS treatment may retain their improvement for longer periods.

Keywords: ADAS-Cog; Alzheimer’s disease; MoCA; cognitive assessments; transcranial magnetic stimulation; treatment

References

  1. PLoS One. 2012;7(8):e42325 - PubMed
  2. Exp Brain Res. 2011 Oct;214(4):549-56 - PubMed
  3. J Neural Transm (Vienna). 2010 Jan;117(1):105-22 - PubMed
  4. J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):794-7 - PubMed
  5. Lancet. 2004 Jun 26;363(9427):2105-15 - PubMed
  6. Mov Disord. 2006 Mar;21(3):325-31 - PubMed
  7. Brain Stimul. 2010 Apr;3(2):95-118 - PubMed
  8. J Clin Neurophysiol. 1991 Jan;8(1):26-37 - PubMed
  9. CMAJ. 2003 Sep 16;169(6):557-64 - PubMed
  10. J Neural Transm (Vienna). 2011 Mar;118(3):463-71 - PubMed
  11. Drugs Aging. 2008;25(8):707-14 - PubMed
  12. Neurosci J. 2013;2013:679389 - PubMed
  13. J Am Geriatr Soc. 2005 Apr;53(4):695-9 - PubMed
  14. Psychol Aging. 1992 Dec;7(4):622-31 - PubMed
  15. Psychiatry Clin Neurosci. 2011 Feb;65(1):77-81 - PubMed
  16. Eur J Neurol. 2008 Dec;15(12):1286-92 - PubMed
  17. Alzheimers Dement. 2013 Sep;9(5):529-37 - PubMed
  18. Eur J Neurosci. 2003 Jun;17(11):2462-8 - PubMed
  19. Cephalalgia. 2010 Jan;30(1):46-52 - PubMed
  20. Psychiatr Pol. 2014 Mar-Apr;48(2):319-30 - PubMed
  21. Neuropsychol Rehabil. 2011 Oct;21(5):703-16 - PubMed
  22. J Neural Transm (Vienna). 2013 May;120(5):813-9 - PubMed
  23. Psychiatry Res. 2002 Oct 1;115(3):101-13 - PubMed
  24. Restor Dent Endod. 2013 Feb;38(1):52-4 - PubMed
  25. Int J Alzheimers Dis. 2012;2012:687909 - PubMed
  26. Acta Neurol Scand. 2014 Jun;129(6):351-66 - PubMed
  27. J Am Geriatr Soc. 2013 Dec;61(12):2252-4 - PubMed
  28. J Neuropsychiatry Clin Neurosci. 2002 Fall;14(4):406-15 - PubMed
  29. Am J Alzheimers Dis Other Demen. 2014 May;29(3):248-55 - PubMed
  30. Exp Brain Res. 2000 Aug;133(4):425-30 - PubMed
  31. Am J Psychiatry. 2004 Mar;161(3):515-24 - PubMed
  32. Neurochem Int. 2000 Apr;36(4-5):471-82 - PubMed
  33. J Vis Exp. 2011 May 23;(51):null - PubMed
  34. Arch Neurol. 2006 Nov;63(11):1602-4 - PubMed
  35. J Neurol. 2012 Jan;259(1):83-92 - PubMed
  36. Am J Psychiatry. 1984 Nov;141(11):1356-64 - PubMed
  37. Int Psychogeriatr. 2014 Mar;26(3):383-91 - PubMed

Publication Types